The goal is to make a low-cost corona vaccine! The vaccine is being prepared by an Indian company
Panacea Biotech Ltd., an Indian company, has entered the field to prepare the corona vaccine. Refana, a US biotechnology company, is helping them with this. Companies like Bharat Biotech, Serum Institute of India also started corona vaccine preparation.
Indian company Panacea Biotech Limited is developing an inactivated covid vaccine by deactivating the SARS Cov 2 viral strain. Rajesh Jain, Managing Director of the company, said, “Vaccines made in this way are much safer and will build long-term immunity in the patient’s body. Refana is helping us in this initiative. The vaccine will hit the Indian market early next year in a joint effort by the two companies. The vaccine will be distributed to other countries in the world with the help of US biotech companies. ”
Panacea Biotech has decided to make a different method of vaccine from Bharat Biotech, Seram Institute of India. The company wants to inactivate the infectious vaccine and inject it into the body. That is, they want to pick up thorns with a kind of thorn. He is always weakened and used to make vaccines or vaccine candidates. The SARS-COV-2 viral strain has been used to make vaccines after inactivating surface proteins or spike glycoproteins and purifying them. Purified viral strains do not have the ability to spread the infection, so these viral strains cannot become active in the patient’s body. Once in the body, it will act as an antigen to prevent the production of antibodies in the body cells. ”
So far, about 50 doses of the vaccine have been planned, said Rajesh Jain, managing director of the company. However, the company plans to bring the vaccine to the market at a lower price to reach all people in the country. If the trial of the vaccine in the human body is successful, the company said that it will initially bring the dose of 40 million vaccines to the market by the beginning of next year. Panacea Biotech is one of the leading pharmaceutical companies in the country. Apart from Delhi, the company has research units in five other Indian states.